A FAP-Targeted SMDC Platform Enables Synergistic Radionuclide-Chemotherapy with PET-Guided Evaluation.

Ruitao Yang, Hongxin Li, Zexin Xu, Baocheng Chen, Ningjie Li, Yuhua Zhong, Kongzhen Hu

Abstract read

In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ruitao YangDepartment of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Hongxin LiDepartment of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Zexin XuDepartment of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Baocheng ChenDepartment of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Ningjie LiDepartment of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Yuhua ZhongDepartment of Rehabilitation Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-6487-3893

Kongzhen HuDepartment of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

National Natural Science Foundation 82272032National Natural Science Foundation 82272585

6 · The paper itself

Abstract

Fibroblast activation protein (FAP) is an attractive stromal target for cancer theranostics; however, developing agents that enable non-invasive pharmacokinetic visualization while achieving effective combined radio-chemotherapy remains challenging. Here we report an imaging-enabled FAP-targeted small molecule-drug conjugate (SMDC) platform that supports PET-based pharmacokinetic visualization and synergistic radionuclide-chemotherapy using matched radiolabeled constructs. In this system,

Indexed as

Membrane ProteinsNeoplasmsPositron-Emission TomographyRadiopharmaceuticalsAnimalsCell Line, TumorEndopeptidasesFemaleFibroblast Activation Protein AlphaGallium RadioisotopesHumansLutetiumMiceTissue DistributionEndopeptidasesFibroblast Activation Protein AlphaGallium RadioisotopesLutetiumMembrane ProteinsRadiopharmaceuticalscleavable linkerfibroblast activation protein (FAP)radio–chemo therapysmall molecule drug conjugates (SMDCs)theranostics

Identifiers

PMID41944234

DOI10.1002/advs.75150

PMCPMC13317686

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.